Business context and reporting period
The filing is Synthetic Biologics, Inc.’s unaudited Form 10-Q for the three months ended March 31, 2015. The source identifies the issuer as Synthetic Biologics, Inc., not Theriva Biologics, Inc. The company describes itself as a clinical-stage biotechnology business developing microbiome-focused therapies and other drug candidates. It reported no product revenue for the quarter.
Programs included SYN-004 for preventing C. difficile infection, SYN-010 for IBS-C, SYN-005 for Pertussis, an Acinetobacter antibody program, and Trimesta for multiple sclerosis. SYN-004 entered Phase 2a in March 2015; the company expected a Phase 2b study in the second half of 2015. SYN-010 Phase 2 initiation was planned for the second quarter of 2015, subject to an IND filing.
Financial results and liquidity
| Metric | Q1 2015 | Q1 2014 / comparison |
|---|---|---|
| Revenue | No product revenue reported | No revenue value presented in the statements |
| General and administrative expense | $1.713 million | $1.122 million; up 53% |
| Research and development expense | $6.494 million | $2.717 million; up 139% |
| Operating loss | $8.207 million | $3.839 million |
| Other expense | $4.151 million, primarily a $4.152 million noncash warrant fair-value loss | $1,000 other income |
| Net loss / loss per share | $12.358 million / $0.17 | $3.838 million / $0.07 |
| Cash used in operating activities | $5.458 million | $3.470 million |
Cash and cash equivalents were $12.049 million at March 31, 2015, down $5.476 million from December 31, 2014. Total assets were $13.716 million. Current and total liabilities were $15.341 million, including $10.908 million of warrant liabilities; the filing does not report borrowings or conventional debt. Stockholders’ deficit was $1.625 million, compared with equity of $9.556 million at year-end 2014. The company had an accumulated deficit of $113.4 million.
Margins are not meaningful given the absence of reported product revenue. No explicit cash-runway estimate is provided. The company has generally incurred negative operating cash flow and stated it had no committed financing sources.
Material changes, outlook, and risks
- Operating expenses rose with expanded clinical, manufacturing, research, and personnel activity. The company attributed higher G&A partly to employee costs, audit procedures, and stock compensation.
- The $4.152 million warrant remeasurement charge was noncash and reflected an increase in the company’s share price. The warrant liability rose from $6.756 million at year-end to $10.908 million.
- R&D included a $1.0 million expense for a milestone under the Prev ABR asset purchase agreement, with shares reportedly issued in April. Separately, the filing reports 212,843 shares valued at $350,000 issued for milestone payments. The described milestone amounts and timing are not clearly reconciled in the filing text.
- Management expected continued substantial spending on development and clinical trials. Further financing could be needed sooner or in greater amounts than anticipated; funding availability and acceptable terms were uncertain, and equity financing could dilute shareholders. Failure to obtain funding could force the company to curtail operations or development.
- The company warned that its $1.625 million stockholders’ deficit could threaten NYSE MKT continued-listing compliance, which it described as requiring $6.0 million of equity under the applicable loss criteria. Delisting could impair liquidity and access to capital.
- Management reported effective disclosure controls as of March 31, 2015, and no material change in internal control over financial reporting during the quarter. The filing reports no legal proceedings and no material risk-factor changes apart from the financing and listing risks described.
Important facts for investors to verify
- Confirm the issuer identity: this source filing is for Synthetic Biologics, Inc., although the request metadata names Theriva Biologics, Inc.
- Check the Prev ABR milestone accounting and share-issuance dates and values; the $350,000 and $1.0 million disclosures are not clearly reconciled.
- Assess the company’s cash needs, financing prospects, and potential dilution, since no committed financing was disclosed.
- Monitor NYSE MKT listing compliance given the reported stockholders’ deficit.
- Track clinical milestones and regulatory progress; the stated 2015 trial timelines are management expectations, not assurances of completion or success.